RenalSense Announces Distribution Agreement with Gloryway in Mainland China

RenalSense™, an Israeli company specializing in real-time renal diagnostics, today announced a distribution agreement with Gloryway, a leading distributor in mainland China of medical devices in anesthesia, airway management, temperature management, and patient monitoring. Gloryway will market and manufacture RenalSense‘s Clarity RMS™ critical care monitoring system to hospitals throughout mainland China.

Clarity RMS has been clinically proven to facilitate early detection of changes in renal function and Acute Kidney Injury (AKI) risk and is installed in a number of intensive care units (ICU) in leading medical centers around the world. Acute kidney injury (AKI) refers to an abrupt decrease in kidney function over hours, days to weeks, resulting in the retention of urea and other nitrogenous waste products and in the dysregulation of extracellular volume and electrolytes. Patients in ICUs are at high risk of contracting AKI and early detection is essential. The mortality rate of AKI is 50-80% in intensive care unit (ICU) patients. The Clarity RMS system continuously measures urine flow, automatically transmitting real-time data and notifications of fluctuations to enable rapid intervention, monitoring of treatment efficacy, and fluid management. Clarity RMS is marketed in Europe, the Middle East, and Africa by Fresenius Medical Care and, in North America by Medline Inc.

“We hope to enhance critical care in China both in the general ICU and COVID-19 ICU by making the Clarity RMS a standard of care, together with Gloryway,” said Avi Kleiman, CEO of RenalSense. “With the annual average cost of AKI over 5.2Billion USD before the COVID-19 pandemic and a rapidly aging population, the need for early detection and treatment monitoring is only growing in the Chinese market.”

“With the introduction of RenalSense to our portfolio, Gloryway will further increase its presence in intensive care units and allow better monitoring of critical patients,” said Tracy Zhang, General Manager of Gloryway.

About Clarity RMS

Clarity RMS is a critical care monitoring system that continuously measures urine flow, automatically transmitting real-time data and notifications of fluctuations, on a 24/7 basis, to the medical staff and EMR. This information, which reflects changes in renal function, has been shown to provide an early sign of risk of acute kidney injury (AKI) to facilitate rapid intervention. In addition, the information is invaluable for monitoring treatment efficacy and managing fluid balance.

About RenalSense

RenalSense is a privately owned medical device company dedicated to real-time renal diagnostics. The company’s first product, Clarity RMS, provides continuous, automatic monitoring for early detection of AKI. RenalSense‘s next-generation products will provide incremental real-time parameters and expanded diagnostic capabilities to further improve the practice of ICU and critical care management.

Learn more about RenalSense at www.renalsense.com

Contact JeanPaul Benhamou, RenalSense  JeanPaul.Benhamou AT renalsense.com

About Gloryway

Gloryway is a medical device company founded in 2000 with headquarters in Beijing and branches in Shanghai, Shenyang, and Guangzhou. Their manufacturing facilities are in Ji’an city. Gloryway is a professional marketing & sales company of medical devices in Anesthesiology, Cardiovascular Surgery, Cardiology, ICU, ER, Airway Management, Temperature Management, and Patient monitoring with strong networks among the industry, industrial societies, and KOLs of specialties. Manufacturers represented by Gloryway are CASMED, LiDCO, Nonin, Vital Signs, King Systems, Aircraft, TSCI, CareEssentials, GVS, Biegler, etc.

Source: Cision PR Newswire Aug 16, 2021
https://www.prnewswire.com/news-releases/renalsense-announces-distribution-agreement-in-mainland-china-with-gloryway-301355436.html

About JLM- BioCity

News on the many life science and healthcare companies in the Jerusalem area can be seen at

https://jlm-biocity.org/jlm-biocity-innovations/.

Join the JLM-BioCity linkedin group at https://www.linkedin.com/groups/7060787 to get the news updates sent to you and to be part of the JLM-BioCity community.

JLM-BioCity  is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.

We invite you, researcher, professional, investor and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.

If you want your Company featured in our blogs , news releases, please contact: info AT jlm-biocity.org